Drug intelligence / Profile preview

EG-006

Development stage: Preclinical
Lead developer: Enhanced Genomics

Overview

EG-006 is a preclinical therapeutic candidate being developed by Enhanced Genomics for the treatment of Alzheimer's disease. The asset was discovered using the company's proprietary 3D multi-omics platform, which maps long-range chromatin interactions to link disease-associated genetic variants in non-coding DNA to their target genes. In June 2025, Enhanced Genomics partnered with the ALBORADA Drug Discovery Institute at the University of Cambridge to accelerate target discovery for Alzheimer's disease, utilizing this 3D multi-omics approach to identify causal biology. EG-006 is currently undergoing preclinical evaluation.

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on EG-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG-006.

Explore the full profile